Xavier Leleu Selected Research

Dexamethasone (Maxidex)

1/2022	All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.
1/2022	Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
1/2022	Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
1/2022	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
1/2022	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
1/2022	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
1/2022	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
1/2022	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
12/2021	Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
12/2021	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xavier Leleu Research Topics

Disease

124	Multiple Myeloma 01/2022 - 08/2002
45	Waldenstrom Macroglobulinemia (Macroglobulinemia) 08/2019 - 05/2006
42	Neoplasms (Cancer) 10/2021 - 10/2003
15	Disease Progression 10/2021 - 05/2008
9	Paraproteinemias (Monoclonal Gammopathy) 03/2013 - 08/2007
8	Neutropenia 01/2022 - 01/2016
7	Peripheral Nervous System Diseases (PNS Diseases) 10/2021 - 05/2011
7	Lymphoma (Lymphomas) 01/2021 - 01/2007
6	Infections 01/2021 - 01/2006
6	Anemia 01/2019 - 01/2006
6	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2013 - 02/2004
5	Pneumonia (Pneumonitis) 01/2022 - 01/2019
5	Venous Thromboembolism 01/2022 - 10/2013
5	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2016
4	Lymphopenia (Lymphocytopenia) 11/2021 - 01/2019
4	Immunoglobulin Light-chain Amyloidosis 10/2020 - 09/2007
4	Residual Neoplasm 01/2019 - 12/2016
4	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2019 - 10/2003
4	Monoclonal Gammopathy of Undetermined Significance 10/2017 - 10/2005
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 01/2018
3	Frailty 01/2021 - 01/2020
3	Amyloidosis 10/2020 - 09/2012
3	Cytopenia 08/2014 - 06/2008
3	Leukemia 12/2010 - 01/2009
2	Sepsis (Septicemia) 01/2022 - 12/2019
2	Urinary Tract Infections (Urinary Tract Infection) 01/2022 - 12/2019
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 01/2016
2	Smoldering Multiple Myeloma 01/2022 - 03/2016
2	Pain (Aches) 10/2021 - 06/2013
2	Fatigue 11/2020 - 01/2016
2	Agammaglobulinemia (Hypogammaglobulinemia) 01/2019 - 06/2008
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019 - 10/2003
2	Febrile Neutropenia 01/2019 - 03/2018
2	Plasmacytoma 01/2018 - 05/2011
2	Plasma Cell Leukemia 01/2016 - 12/2015
2	Carcinogenesis 01/2014 - 09/2002
2	Hematologic Neoplasms (Hematological Malignancy) 01/2013 - 09/2012
2	Thrombosis (Thrombus) 12/2012 - 10/2012
2	Cryoglobulinemia 09/2012 - 06/2008
2	Second Primary Neoplasms (Neoplasms, Second) 05/2012 - 02/2004
2	B-Cell Lymphoma (Lymphoma, B Cell) 02/2011 - 05/2008

Drug/Important Bio-Agent (IBA)

61	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 11/2006
41	Bortezomib (Velcade)FDA Link 01/2022 - 11/2006
36	Lenalidomide (CC 5013)FDA Link 01/2022 - 01/2009
20	Immunoglobulin M (IgM)IBA 10/2017 - 08/2007
15	carfilzomibIBA 01/2022 - 05/2015
14	daratumumabIBA 01/2022 - 01/2019
14	Thalidomide (Thalomid)FDA Link 10/2021 - 08/2002
13	pomalidomideIBA 01/2022 - 03/2013
13	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 03/2007
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2006
13	Proteasome InhibitorsIBA 01/2022 - 04/2009
12	Immunomodulating AgentsIBA 09/2021 - 10/2012
10	Monoclonal AntibodiesIBA 10/2021 - 05/2006
9	isatuximabIBA 01/2022 - 12/2019
9	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 01/2006
8	Pharmaceutical PreparationsIBA 10/2021 - 05/2011
7	selinexorIBA 01/2022 - 11/2020
7	ixazomibIBA 01/2022 - 05/2018
7	Prednisone (Sone)FDA LinkGeneric 01/2019 - 02/2004
7	Rituximab (Mabthera)FDA Link 11/2017 - 01/2007
5	Biological ProductsIBA 01/2016 - 09/2002
4	melflufenIBA 01/2022 - 10/2020
4	Immunologic Factors (Immunomodulators)IBA 09/2021 - 08/2007
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 02/2004
4	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2019 - 05/2008
4	MicroRNAs (MicroRNA)IBA 01/2017 - 04/2009
3	Biomarkers (Surrogate Marker)IBA 12/2021 - 02/2011
3	Peptides (Polypeptides)IBA 10/2021 - 10/2020
3	Alkylating AgentsIBA 01/2021 - 03/2018
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2018
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 02/2004
3	NF-kappa B (NF-kB)IBA 04/2013 - 05/2008
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2007 - 11/2006
2	Immunoglobulin IsotypesIBA 10/2021 - 09/2002
2	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 10/2021 - 01/2020
2	AminopeptidasesIBA 01/2021 - 10/2020
2	Drug CombinationsIBA 11/2020 - 09/2014
2	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2020
2	ResveratrolIBA 08/2019 - 03/2008
2	elotuzumabIBA 11/2018 - 06/2012
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2018 - 01/2016
2	Immunoglobulin G (IgG)IBA 01/2017 - 01/2007
2	Vorinostat FDA Link 01/2016 - 05/2013
2	Amyloid (Amyloid Fibrils)IBA 08/2015 - 12/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 10/2007
2	Antineoplastic Agents (Antineoplastics)IBA 08/2013 - 05/2008
2	ParaproteinsIBA 04/2013 - 04/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2013 - 02/2008
2	LigandsIBA 12/2010 - 08/2007

Therapy/Procedure

65	Therapeutics 01/2022 - 06/2007
17	Stem Cell Transplantation 11/2021 - 11/2006
10	Drug Therapy (Chemotherapy) 11/2021 - 09/2002
8	Transplantation 01/2022 - 05/2012
3	Immunotherapy 10/2021 - 12/2010
3	Intravenous Administration 12/2012 - 12/2008
3	Subcutaneous Injections 12/2012 - 12/2008
3	Aftercare (After-Treatment) 09/2009 - 02/2004
2	Radiotherapy 01/2016 - 06/2013
2	Autologous Transplantation 08/2014 - 01/2014